Published in Eur Neuropsychopharmacol on September 01, 2017
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform (2008) 71.12
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 65.11
FSL. Neuroimage (2011) 15.56
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry (2003) 13.60
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev (1998) 12.19
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci (2001) 10.05
Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab (1996) 9.49
Parsing reward. Trends Neurosci (2003) 7.88
The mesolimbic dopamine reward circuit in depression. Biol Psychiatry (2006) 7.62
Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp (1994) 7.28
Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci (2000) 6.02
Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport (2001) 4.99
The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry (2007) 4.51
Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res (1991) 4.30
A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry (1995) 3.89
State-dependent opioid control of pain. Nat Rev Neurosci (2004) 3.51
Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry (2008) 3.47
Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev (2010) 3.46
Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci U S A (2007) 3.33
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 3.18
A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol (1984) 3.11
Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness? J Neurosci (2005) 3.10
Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One (2010) 3.03
Individual differences in reward responding explain placebo-induced expectations and effects. Neuron (2007) 2.96
Placebo in emotional processing--induced expectations of anxiety relief activate a generalized modulatory network. Neuron (2005) 2.90
Choice selection and reward anticipation: an fMRI study. Neuropsychologia (2004) 2.52
Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. Nature (2012) 2.19
Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci (2003) 2.00
The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov (2013) 2.00
A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry (2004) 1.94
Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med (1993) 1.93
Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry (2009) 1.63
Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab (1997) 1.55
Nucleus accumbens corticotropin-releasing factor increases cue-triggered motivation for sucrose reward: paradoxical positive incentive effects in stress? BMC Biol (2006) 1.49
Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression. JAMA Psychiatry (2015) 1.48
Neural representation of reward in recovered depressed patients. Psychopharmacology (Berl) (2009) 1.43
Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy. Neuropsychopharmacology (2012) 1.38
The amygdalostriatal projections in the monkey. An anterograde tracing study. Brain Res (1985) 1.37
Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res (2002) 1.36
Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand (2001) 1.31
Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature. Synapse (2008) 1.27
Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry (2015) 1.25
Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry (2006) 1.15
Nucleus accumbens dopamine/glutamate interaction switches modes to generate desire versus dread: D(1) alone for appetitive eating but D(1) and D(2) together for fear. J Neurosci (2011) 1.10
Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med (1997) 1.08
Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry (1994) 1.06
Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry (2001) 1.04
Amygdaloid inputs define a caudal component of the ventral striatum in primates. J Comp Neurol (2004) 0.97
Time-to-remission from geriatric depression: psychosocial and clinical factors. Am J Geriatr Psychiatry (2002) 0.95
Greater availability of dopamine transporters in patients with major depression--a dual-isotope SPECT study. Psychiatry Res (2008) 0.95
Dopamine and depression--striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl) (1996) 0.95
Functions of mesolimbic dopamine: changing concepts and shifting paradigms. Psychopharmacology (Berl) (2006) 0.95
Dopaminergic activity in depressed smokers: a positron emission tomography study. Synapse (2009) 0.94
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety (2002) 0.93
Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry (2005) 0.92
Striatal and central extended amygdala parts of the interstitial nucleus of the posterior limb of the anterior commissure: evidence from tract-tracing techniques in the rat. J Comp Neurol (2001) 0.87
Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res (1999) 0.83
The treatment of depression in patients with advanced cancer undergoing palliative care. Curr Opin Support Palliat Care (2009) 0.82
Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/3 receptors in major depressive disorder studied with [11C]raclopride PET. J Psychopharmacol (2010) 0.81
Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J Affect Disord (2007) 0.79
An explanation for the placebo effect? Science (2005) 0.77
Bromocriptine in depression. Curr Med Res Opin (1982) 0.76
Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495). Neuropsychobiology (1978) 0.76